GLAM
CERE

Gardner Lewis Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Gardner Lewis Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-192,150
Closed -$7.86M – 74
2024
Q2 		$7.86M Buy
192,150
+70,000
+57% +$2.92M 2.15% 18
2024
Q1 		$5.16M Buy
+122,150
New +$5.13M 1.41% 25

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Gardner Lewis Asset Management's CERE Position: Q3 2024 in Review

Gardner Lewis Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 192,150 shares — an estimated $7.86M sold.

Gardner Lewis Asset Management first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $7.86M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Gardner Lewis Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Gardner Lewis Asset Management sold 192,150 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.86M.
  • Gardner Lewis Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Gardner Lewis Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $7.86M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Gardner Lewis Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.